<DOC>
	<DOCNO>NCT00497796</DOCNO>
	<brief_summary>The purpose research study investigate whether oral maribavir safe effective compare oral ganciclovir prevent CMV disease administer 14 week patient liver transplant .</brief_summary>
	<brief_title>Maribavir Versus Oral Ganciclovir For The Prevention Cytomegalovirus ( CMV ) Disease Liver Transplant Recipients</brief_title>
	<detailed_description>Cytomegalovirus ( CMV ) infection remain significant problem follow various type transplant associate strong immunosuppressive therapy . Maribavir new oral anti-CMV drug novel mechanism action compare currently available anti-CMV drug . This study test safety efficacy maribavir prevention CMV disease give prophylaxis 14 week follow orthotopic liver transplantation .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Orthotopic liver transplant recipient Donor CMV seropositive / Recipient CMV seronegative Enrolled within 10 day liver transplant Able swallow tablet Multiple organ transplant HIV infection CMV disease Use antiCMV therapy time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>cytomegalovirus</keyword>
	<keyword>CMV</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>liver</keyword>
	<keyword>liver transplant</keyword>
</DOC>